Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) major shareholder Ra Capital Management, Llc sold 4,235,000 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $9.53, for a total value of $40,359,550.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 3.46% during mid-day trading on Tuesday, hitting $9.87. 7,249,328 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $10.10. The stock has a 50-day moving average of $7.43 and a 200-day moving average of $4.69. The company’s market cap is $965.2 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.69 EPS for the current fiscal year.

A number of analysts have recently weighed in on ACHN shares. Analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $6.00. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Finally, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $8.90.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Receive News & Ratings for Achillion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.